Regulus Therapeutics
Regulus Therapeutics – A Leading microRNA Therapeutics Company | Regulus Therapeutics – a leading company developing microRNA therapeutics. Medicines that target the pathways of human disease..
Launch date
Employees
Market cap
AUD163m
Enterprise valuation
AUD18m (Public information from Sep 2024)
Share price
$1.71 RGLS
San Diego California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 10.0m | - | - | - | - | - | - |
| % growth | 46 % | - | - | - | - | - | - |
| EBITDA | (14.2m) | (27.8m) | (28.2m) | (29.2m) | (45.8m) | (54.7m) | - |
| % EBITDA margin | (141 %) | - | - | - | - | - | - |
| Profit | (15.7m) | (27.8m) | (28.3m) | (30.0m) | (41.8m) | (66.5m) | (91.0m) |
| % profit margin | (157 %) | - | - | - | - | - | - |
| EV / revenue | 6.4x | - | - | - | - | - | - |
| EV / EBITDA | -4.5x | -1.6x | 0.0x | -0.2x | -0.7x | -1.5x | - |
| R&D budget | 15.3m | 17.8m | 18.4m | 21.2m | - | - | - |
| R&D % of revenue | 153 % | - | - | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $10.0m | Post IPO Equity | |
| N/A | $104m | Post IPO Equity | |
$30.0m | Debt | ||
N/A | - | ||
* | N/A | $43.0m | Post IPO Equity |
| N/A | $16.7m | Post IPO Equity | |
| N/A | $19.4m | Private Placement VC | |
* | N/A | $34.6m | Private Placement VC |
* | $15.0m | Post IPO Equity | |
* | $100m | Private Placement VC | |
| Total Funding | AUD284m | ||
Related Content
Recent News about Regulus Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.